Successful generation of p190-BCR ABL-specific T-cell lines for prophylaxis/treatment of minimal residual disease in HSCT recipients with Ph plus acute lymphoblastic leukaemia

被引：0
|
作者：
Basso, S. [1 ]
Quartuccio, G. [1 ]
Guido, I. [1 ]
Quadrelli, C. [2 ]
Gurrado, A. [1 ]
Piantoni, L. [1 ]
Zavras, N. [1 ]
Cantoni, F. [1 ]
Falcone, R. [1 ]
Riva, G. [2 ]
Barozzi, P. [2 ]
Potenza, L. [2 ]
Maccario, R. [1 ]
Zecca, M. [1 ]
Luppi, M. [2 ]
Comoli, P. [1 ]
机构：
[1] Fdn IRCCS Policlin S Matteo, Pavia, Italy
[2] Modena & Reggio Emilia Univ, Modena, Italy
来源：
BONE MARROW TRANSPLANTATION | 2012年 / 47卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S321 / S321
页数：1
相关论文
共 7 条
  • [1] Monitoring of minimal residual disease in early T-cell precursor acute lymphoblastic leukaemia by next-generation sequencing
    Pan, Xiaoqing
    Nariai, Naoki
    Fukuhara, Noriko
    Saito, Sakae
    Sato, Yukuto
    Katsuoka, Fumiki
    Kojima, Kaname
    Kuroki, Yoko
    Danjoh, Inaho
    Saito, Rumiko
    Hasegawa, Shin
    Okitsu, Yoko
    Kondo, Aiko
    Onishi, Yasushi
    Nagami, Fuji
    Kiyomoto, Hideyasu
    Hozawa, Atsushi
    Fuse, Nobuo
    Nagasaki, Masao
    Shimizu, Ritsuko
    Yasuda, Jun
    Harigae, Hideo
    Yamamoto, Masayuki
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (02) : 318 - 321
  • [2] Low level expression of BCR-ABL (p190) in Philadelphia negative paediatric acute lymphoblastic leukaemia presents difficulties with diagnosis and with monitoring of minimal residual disease
    Holt, DS
    Thomas, A
    Austin, SJ
    Mills, KI
    Thropp, S
    Rafiq, A
    Birdsall, S
    Burnett, AK
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 : 22 - 22
  • [3] QUANTITATION OF MINIMAL RESIDUAL DISEASE BY COMPETITIVE PCR FOR P190 BCR-ABL MESSENGER-RNA IN PH-POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA (ALL)
    VANRHEE, F
    MARKS, DI
    FENG, L
    CROSS, NCP
    GOLDMAN, JM
    BLOOD, 1993, 82 (10) : A442 - A442
  • [4] A rare case of Philadelphia-positive (P210BCR-ABL1) T-cell acute lymphoblastic leukemia/lymphoma associated with minimal residual disease persistence after intensive chemotherapeutic approaches
    Shah, Shruti
    Kundu, Rupayan
    Mishra, Rahul
    Mukherjee, Sudipto
    Singh, Abhay
    LEUKEMIA RESEARCH REPORTS, 2024, 21
  • [5] IMPACT OF ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) ON MINIMAL RESIDUAL DISEASE (MRD) AND BCR-ABL KINASE DOMAIN MUTATIONS IN PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH plus ALL)
    Pfeifer, H.
    Wystub, S.
    Wassmann, B.
    Brueck, P.
    Goekbuget, N.
    Wunderle, L.
    Chromik, J.
    Serve, H.
    Hoelzer, D.
    Ottmann, O. G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 368 - 368
  • [6] Development and Validation of a Highly Sensitive ela2 (p190) BCR-ABL Test to Determine Complete Molecular Response (Minimal Residual Disease Negative) As a Primary Endpoint for Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph plus ALL)
    Drafahl, Kristy
    Smith, David C.
    Graham, Cristen
    Glynn, Christine
    Spittle, Cindy
    Verrow, Scott
    Rivera, Victor M.
    Srivastava, Shouryadeep
    Hawkins, Kevin
    Galderisi, Chad
    BLOOD, 2018, 132
  • [7] Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies
    Cazzaniga, Giovanni
    De Lorenzo, Paola
    Alten, Julia
    Roettgers, Silja
    Hancock, Jeremy
    Saha, Vaskar
    Castor, Anders
    Madsen, Hans O.
    Gandemer, Virginie
    Cave, Helene
    Leoni, Veronica
    Koehler, Rolf
    Ferrari, Giulia M.
    Bleckmann, Kirsten
    Pieters, Rob
    van der Velden, Vincent
    Stary, Jan
    Zuna, Jan
    Escherich, Gabriele
    zur Stadt, Udo
    Arico, Maurizio
    Conter, Valentino
    Schrappe, Martin
    Valsecchi, Maria Grazia
    Biondi, Andrea
    HAEMATOLOGICA, 2018, 103 (01) : 107 - 115
1